Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice
Curcumin reduces Hodgkin's lymphoma (HL) cell growth in vitro, but its unfavorable pharmacokinetics highlight the need for novel in vivo delivery systems. Thus, we explored whether formulation of curcumin in solid lipid nanoparticles (SLN-curc) or d-α-Tocopheryl polyethylene glycol 1000 succina...
Saved in:
| Published in: | Archives of biochemistry and biophysics Vol. 648; pp. 12 - 19 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Inc
15-06-2018
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Curcumin reduces Hodgkin's lymphoma (HL) cell growth in vitro, but its unfavorable pharmacokinetics highlight the need for novel in vivo delivery systems. Thus, we explored whether formulation of curcumin in solid lipid nanoparticles (SLN-curc) or d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) nanoparticles (TPGS-curc) could enhance its efficacy in mice. Curcumin formulated in SLN and in TPGS resulted in higher curcumin plasma levels in mice. Compared to vehicle-treated controls, SLN-curc and TPGS-curc reduced HL xenograft growth by 50.5% (p < 0.02) and 43.0% (p < 0.04), respectively, while curcumin reduced it by 35.8% (p < 0.05). In addition, SLN-curc reduced the expression of proteins involved in cell proliferation and apoptosis (XIAP and Mcl-1) in HL tumor extracts. In HL cells in culture, curcumin decreased the expression of relevant anti-inflammatory cytokines (IL-6 and TNF-α) in a concentration-dependent manner. Moreover, when given in combination with bleomycin, doxorubicin and vinblastine, curcumin showed an additive growth inhibitory effect. In conclusion, SLNs appear as an appropriate and effective drug delivery system for curcumin. Given the efficacy of SLN-curc and the enhanced growth inhibitory effect when combined with chemotherapeutic drugs, we speculate that curcumin, when appropriately formulated, is a promising adjuvant agent for the treatment of HL and merits further evaluation.
•Curcumin formulated in solid lipid nanoparticles (SLNs) improves its plasma levels.•Curcumin formulated in SLN reduces Hodgkin's lymphoma (HL) xenograft growth.•Curcumin reduces the levels of inflammatory cytokines in HL cells.•Curcumin enhances the growth inhibitory effect of HL chemotherapeutic drugs. |
|---|---|
| AbstractList | Curcumin reduces Hodgkin's lymphoma (HL) cell growth in vitro, but its unfavorable pharmacokinetics highlight the need for novel in vivo delivery systems. Thus, we explored whether formulation of curcumin in solid lipid nanoparticles (SLN-curc) or d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) nanoparticles (TPGS-curc) could enhance its efficacy in mice. Curcumin formulated in SLN and in TPGS resulted in higher curcumin plasma levels in mice. Compared to vehicle-treated controls, SLN-curc and TPGS-curc reduced HL xenograft growth by 50.5% (p < 0.02) and 43.0% (p < 0.04), respectively, while curcumin reduced it by 35.8% (p < 0.05). In addition, SLN-curc reduced the expression of proteins involved in cell proliferation and apoptosis (XIAP and Mcl-1) in HL tumor extracts. In HL cells in culture, curcumin decreased the expression of relevant anti-inflammatory cytokines (IL-6 and TNF-α) in a concentration-dependent manner. Moreover, when given in combination with bleomycin, doxorubicin and vinblastine, curcumin showed an additive growth inhibitory effect. In conclusion, SLNs appear as an appropriate and effective drug delivery system for curcumin. Given the efficacy of SLN-curc and the enhanced growth inhibitory effect when combined with chemotherapeutic drugs, we speculate that curcumin, when appropriately formulated, is a promising adjuvant agent for the treatment of HL and merits further evaluation. Curcumin reduces Hodgkin's lymphoma (HL) cell growth in vitro, but its unfavorable pharmacokinetics highlight the need for novel in vivo delivery systems. Thus, we explored whether formulation of curcumin in solid lipid nanoparticles (SLN-curc) or d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) nanoparticles (TPGS-curc) could enhance its efficacy in mice. Curcumin formulated in SLN and in TPGS resulted in higher curcumin plasma levels in mice. Compared to vehicle-treated controls, SLN-curc and TPGS-curc reduced HL xenograft growth by 50.5% (p < 0.02) and 43.0% (p < 0.04), respectively, while curcumin reduced it by 35.8% (p < 0.05). In addition, SLN-curc reduced the expression of proteins involved in cell proliferation and apoptosis (XIAP and Mcl-1) in HL tumor extracts. In HL cells in culture, curcumin decreased the expression of relevant anti-inflammatory cytokines (IL-6 and TNF-α) in a concentration-dependent manner. Moreover, when given in combination with bleomycin, doxorubicin and vinblastine, curcumin showed an additive growth inhibitory effect. In conclusion, SLNs appear as an appropriate and effective drug delivery system for curcumin. Given the efficacy of SLN-curc and the enhanced growth inhibitory effect when combined with chemotherapeutic drugs, we speculate that curcumin, when appropriately formulated, is a promising adjuvant agent for the treatment of HL and merits further evaluation. Curcumin reduces Hodgkin's lymphoma (HL) cell growth in vitro, but its unfavorable pharmacokinetics highlight the need for novel in vivo delivery systems. Thus, we explored whether formulation of curcumin in solid lipid nanoparticles (SLN-curc) or d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) nanoparticles (TPGS-curc) could enhance its efficacy in mice. Curcumin formulated in SLN and in TPGS resulted in higher curcumin plasma levels in mice. Compared to vehicle-treated controls, SLN-curc and TPGS-curc reduced HL xenograft growth by 50.5% (p < 0.02) and 43.0% (p < 0.04), respectively, while curcumin reduced it by 35.8% (p < 0.05). In addition, SLN-curc reduced the expression of proteins involved in cell proliferation and apoptosis (XIAP and Mcl-1) in HL tumor extracts. In HL cells in culture, curcumin decreased the expression of relevant anti-inflammatory cytokines (IL-6 and TNF-α) in a concentration-dependent manner. Moreover, when given in combination with bleomycin, doxorubicin and vinblastine, curcumin showed an additive growth inhibitory effect. In conclusion, SLNs appear as an appropriate and effective drug delivery system for curcumin. Given the efficacy of SLN-curc and the enhanced growth inhibitory effect when combined with chemotherapeutic drugs, we speculate that curcumin, when appropriately formulated, is a promising adjuvant agent for the treatment of HL and merits further evaluation. •Curcumin formulated in solid lipid nanoparticles (SLNs) improves its plasma levels.•Curcumin formulated in SLN reduces Hodgkin's lymphoma (HL) xenograft growth.•Curcumin reduces the levels of inflammatory cytokines in HL cells.•Curcumin enhances the growth inhibitory effect of HL chemotherapeutic drugs. |
| Author | Wang, Ruixue Mattheolabakis, George Mackenzie, Gerardo G. Guorgui, Jacob |
| Author_xml | – sequence: 1 givenname: Jacob surname: Guorgui fullname: Guorgui, Jacob organization: Department of Nutrition, University of California, Davis, One Shields Ave, Davis, CA, 95616, USA – sequence: 2 givenname: Ruixue surname: Wang fullname: Wang, Ruixue organization: Department of Family, Population and Preventive Medicine, Stony Brook University, Stony Brook, NY, 11794-8175, USA – sequence: 3 givenname: George surname: Mattheolabakis fullname: Mattheolabakis, George organization: Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, Monroe, LA, 71201, USA – sequence: 4 givenname: Gerardo G. orcidid: 0000-0002-6460-7165 surname: Mackenzie fullname: Mackenzie, Gerardo G. email: ggmackenzie@ucdavis.edu organization: Department of Nutrition, University of California, Davis, One Shields Ave, Davis, CA, 95616, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29679536$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kDFv2zAQhYkiQWMn_QFZCm3JIuUoyrSIToGRxgUMdElmgqKONR2JVEkpgP99KNjtmOV4R7z3gPctyYXzDgm5pVBQoPzhUKimKUqgdQFVAbT8QhYUBM-B1dUFWQAAy0XN6RVZxngAoLTi5VdyVQq-FivGF6TdTEFPvXWZ8aGfOjVim6Ur-s62WWeHNJ1yflBhtLrDmO1VzNDtldNJicZYrfRxtmx9--fNuruYdcd-2Ptezb-91XhDLo3qIn47v9fk9efTy2ab734__9o87nLNBB9z1iIzNYM2dYCyppVKuxZVoxmn65UQDU-NFIKpaFNypYzhJWUcTbJxs2LX5P6UOwT_d8I4yt5GjV2nHPopyjKlimrNakhSepLq4GMMaOQQbK_CUVKQM1x5kAmunOFKqGSCmzzfz_FT02P73_GPZhL8OAkwlXy3GGTUFmdQNqAeZevtJ_EfrHKL4A |
| CitedBy_id | crossref_primary_10_1515_dmpt_2018_0032 crossref_primary_10_3390_biomedicines10092153 crossref_primary_10_3390_molecules27154818 crossref_primary_10_1177_0300060520943792 crossref_primary_10_3390_pharmaceutics12111084 crossref_primary_10_2174_1389200223666220416213639 crossref_primary_10_2174_2210681209666190417144126 crossref_primary_10_1016_j_jtcme_2023_10_004 crossref_primary_10_3390_molecules27175452 crossref_primary_10_1016_j_abb_2018_05_022 crossref_primary_10_3390_antibiotics11020135 crossref_primary_10_3390_pharmaceutics15030981 crossref_primary_10_34172_apb_2023_087 crossref_primary_10_1016_j_ijpharm_2019_118787 crossref_primary_10_1007_s13346_021_01097_z crossref_primary_10_2174_0113895575258798230927061557 crossref_primary_10_3390_ijms25084432 crossref_primary_10_1007_s10311_020_01042_5 crossref_primary_10_1016_j_addr_2022_114445 crossref_primary_10_1016_j_jddst_2022_103982 crossref_primary_10_2174_1381612829666230613115447 crossref_primary_10_2174_1389557520666200429103647 crossref_primary_10_1016_j_foodhyd_2018_10_003 crossref_primary_10_2174_0929867326666190129142604 crossref_primary_10_1016_j_ijbiomac_2019_08_088 crossref_primary_10_2147_DDDT_S311107 crossref_primary_10_3390_biomedicines9101476 crossref_primary_10_1016_j_sajb_2022_04_021 crossref_primary_10_3390_nano14080672 crossref_primary_10_1155_2022_5926609 crossref_primary_10_1016_j_abb_2020_108546 crossref_primary_10_2174_1574892815999201102214602 crossref_primary_10_3390_nano11102593 crossref_primary_10_18632_aging_203319 crossref_primary_10_3390_pharmaceutics15030831 crossref_primary_10_1007_s13318_019_00545_z crossref_primary_10_2174_2211738510666220304111848 crossref_primary_10_1016_j_bbrc_2019_12_129 crossref_primary_10_1016_j_cis_2020_102210 crossref_primary_10_1016_j_tifs_2019_06_001 crossref_primary_10_3389_fonc_2019_00048 crossref_primary_10_1016_j_leukres_2021_106554 crossref_primary_10_1021_acs_bioconjchem_9b00006 crossref_primary_10_3390_molecules24142527 crossref_primary_10_3390_ph16070943 crossref_primary_10_22159_ijap_2023v15i2_46970 crossref_primary_10_1016_j_colsurfb_2022_112863 crossref_primary_10_3390_nano13212887 |
| Cites_doi | 10.1002/ejp.620 10.1016/j.ejps.2005.04.003 10.1007/s12253-011-9494-4 10.1111/j.1440-1681.2011.05648.x 10.1080/10428194.2017.1376745 10.1182/blood-2004-12-4750 10.1038/nnano.2007.387 10.1002/mnfr.200700354 10.1006/phrs.2000.0695 10.1002/ijc.23477 10.1080/02652040701799598 10.1124/pr.58.3.10 10.1007/s12185-016-2080-5 10.1016/j.msec.2013.07.047 10.1208/s12248-012-9432-8 10.1200/JCO.2017.75.2543 10.1056/NEJMoa1100340 10.1093/annonc/mdx005 10.1080/10611860290031868 10.1016/S0169-409X(01)00105-3 10.1007/s11095-012-0801-x 10.1007/BF02854895 10.1016/j.bcp.2007.08.016 10.1046/j.1365-2141.2002.03575.x 10.1158/1940-6207.CAPR-08-0042 10.3390/pharmaceutics9030024 10.1038/cddis.2016.185 10.1101/cshperspect.a016295 10.3109/10717544.2012.721143 10.3390/pharmaceutics8030024 |
| ContentType | Journal Article |
| Copyright | 2018 Elsevier Inc. Copyright © 2018 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2018 Elsevier Inc. – notice: Copyright © 2018 Elsevier Inc. All rights reserved. |
| DBID | NPM AAYXX CITATION 7X8 |
| DOI | 10.1016/j.abb.2018.04.012 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry Biology |
| EISSN | 1096-0384 |
| EndPage | 19 |
| ExternalDocumentID | 10_1016_j_abb_2018_04_012 29679536 S0003986118301929 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M -DZ -~X .~1 0R~ 1B1 1RT 1~. 1~5 23M 4.4 457 4G. 5GY 5VS 6J9 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAXUO ABFRF ABGSF ABJNI ABMAC ABPPZ ABUDA ABYKQ ACDAQ ACGFO ACGFS ACNCT ACRLP ADBBV ADEZE ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC CS3 DM4 DOVZS EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA HLW IH2 IHE J1W K-O KOM L7B LG5 LX2 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 RIG RNS ROL RPZ SDF SDG SDP SES SPCBC SSU SSZ T5K TWZ WH7 ~02 ~G- AAHBH AAXKI AKRWK NPM .55 .GJ .HR 3O- 53G AAQXK AAYXX ABEFU ABFNM ABXDB ADFGL ADMUD AFJKZ AGHFR AGRDE AHHHB AI. ASPBG AVWKF AZFZN CAG CITATION COF FEDTE FGOYB G-2 HVGLF HZ~ MVM NEJ OHT R2- SBG SEW UQL VH1 WUQ X7M XOL XPP YYP ZGI ZMT ZXP ~KM 7X8 |
| ID | FETCH-LOGICAL-c396t-3de3f830d10902814a30dc94bc3617599b6000ae0f41b26aaff62136ef3f86f53 |
| ISSN | 0003-9861 |
| IngestDate | Fri Oct 25 01:39:35 EDT 2024 Thu Sep 26 16:07:11 EDT 2024 Wed Oct 16 00:50:48 EDT 2024 Fri Feb 23 02:29:36 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Curcumin SLN TPGS Hodgkin's lymphoma |
| Language | English |
| License | Copyright © 2018 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c396t-3de3f830d10902814a30dc94bc3617599b6000ae0f41b26aaff62136ef3f86f53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-6460-7165 |
| OpenAccessLink | https://escholarship.org/content/qt0nt9j1zp/qt0nt9j1zp.pdf?t=pqrqmm |
| PMID | 29679536 |
| PQID | 2028947380 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2028947380 crossref_primary_10_1016_j_abb_2018_04_012 pubmed_primary_29679536 elsevier_sciencedirect_doi_10_1016_j_abb_2018_04_012 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-06-15 |
| PublicationDateYYYYMMDD | 2018-06-15 |
| PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Archives of biochemistry and biophysics |
| PublicationTitleAlternate | Arch Biochem Biophys |
| PublicationYear | 2018 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Zhu, Cheng, Mackenzie, Huang, Sun, Xie, Vrankova, Constantinides, Rigas (bib11) 2012; 29 Zara, Cavalli, Bargoni, Fundaro, Vighetto, Gasco (bib8) 2002; 10 Kamran, Jacene, Chen, Mauch, Ng (bib27) 2017 Viviani, Zinzani, Rambaldi, Brusamolino, Levis, Bonfante, Vitolo, Pulsoni, Liberati, Specchia, Valagussa, Rossi, Zaja, Pogliani, Pregno, Gotti, Gallamini, Rota Scalabrini, Bonadonna, Gianni, Michelangelo, Gruppo (bib18) 2011; 365 Gallamini, Tarella, Viviani, Rossi, Patti, Mule, Picardi, Romano, Cantonetti, La Nasa, Trentin, Bolis, Rapezzi, Battistini, Gottardi, Gavarotti, Corradini, Cimminiello, Schiavotto, Parvis, Zanotti, Gini, Ferreri, Viero, Miglino, Billio, Avigdor, Biggi, Fallanca, Ficola, Gregianin, Chiaravalloti, Prosperini, Bergesio, Chauvie, Pavoni, Gianni, Rambaldi (bib26) 2018; 36 Skoetz, Will, Monsef, Brillant, Engert, von Tresckow (bib28) 2017; 5 Jain, Chaurasiya, Gupta, Jain, Dagur, Joshi, Katoch (bib9) 2008; 25 Reddy, Adhikari, Dwarakanath, Sharma, Murthy (bib10) 2006; 8 Gupta, Patchva, Koh, Aggarwal (bib21) 2012; 39 Peer, Karp, Hong, Farokhzad, Margalit, Langer (bib5) 2007; 2 Tanaka, Narazaki, Kishimoto (bib23) 2014; 6 Varma, Panchagnula (bib16) 2005; 25 Rachmawati, Pradana, Safitri, Adnyana (bib14) 2017; 9 Gupta, Patchva, Aggarwal (bib20) 2013; 15 Fundaro, Cavalli, Bargoni, Vighetto, Zara, Gasco (bib7) 2000; 42 Chou (bib31) 2006; 58 Re, Thomas, Behringer, Diehl (bib1) 2005; 105 Goel, Kunnumakkara, Aggarwal (bib2) 2008; 75 Andjelic, Mihaljevic, Jakovic (bib17) 2012; 18 Wang, Zhang, Peng, Li, Xiong, Xu (bib12) 2013; 33 Goel, Jhurani, Aggarwal (bib3) 2008; 52 Marr, Connors, Savage, Goddard, Deyell (bib29) 2017; 28 Arora, Kuhad, Kaur, Chopra (bib13) 2015; 19 Jiang, Chen, Huang, Chen (bib30) 2016; 104 Meyskens, McLaren, Pelot, Fujikawa-Brooks, Carpenter, Hawk, Kelloff, Lawson, Kidao, McCracken, Albers, Ahnen, Turgeon, Goldschmid, Lance, Hagedorn, Gillen, Gerner (bib19) 2008; 1 Mackenzie, Queisser, Wolfson, Fraga, Adamo, Oteiza (bib4) 2008; 123 Gopas, Stern, Zurgil, Ozer, Ben-Ari, Shubinsky, Braiman, Sinay, Ezratty, Dronov, Balachandran, Benharroch, Livneh (bib25) 2016; 7 Reynolds, Billingham, Gray, Flavell, Najafipour, Crocker, Nelson, Young, Murray (bib24) 2002; 118 Mehnert, Mader (bib6) 2001; 47 Rahman, Cao, Steadman, Wei, Parekh (bib22) 2012; 19 Rachmawati, Safitri, Pradana, Adnyana (bib15) 2016; 8 Rahman (10.1016/j.abb.2018.04.012_bib22) 2012; 19 Peer (10.1016/j.abb.2018.04.012_bib5) 2007; 2 Rachmawati (10.1016/j.abb.2018.04.012_bib15) 2016; 8 Wang (10.1016/j.abb.2018.04.012_bib12) 2013; 33 Jain (10.1016/j.abb.2018.04.012_bib9) 2008; 25 Tanaka (10.1016/j.abb.2018.04.012_bib23) 2014; 6 Jiang (10.1016/j.abb.2018.04.012_bib30) 2016; 104 Varma (10.1016/j.abb.2018.04.012_bib16) 2005; 25 Andjelic (10.1016/j.abb.2018.04.012_bib17) 2012; 18 Kamran (10.1016/j.abb.2018.04.012_bib27) 2017 Goel (10.1016/j.abb.2018.04.012_bib3) 2008; 52 Gopas (10.1016/j.abb.2018.04.012_bib25) 2016; 7 Marr (10.1016/j.abb.2018.04.012_bib29) 2017; 28 Zara (10.1016/j.abb.2018.04.012_bib8) 2002; 10 Gupta (10.1016/j.abb.2018.04.012_bib21) 2012; 39 Mackenzie (10.1016/j.abb.2018.04.012_bib4) 2008; 123 Gallamini (10.1016/j.abb.2018.04.012_bib26) 2018; 36 Reddy (10.1016/j.abb.2018.04.012_bib10) 2006; 8 Fundaro (10.1016/j.abb.2018.04.012_bib7) 2000; 42 Goel (10.1016/j.abb.2018.04.012_bib2) 2008; 75 Rachmawati (10.1016/j.abb.2018.04.012_bib14) 2017; 9 Reynolds (10.1016/j.abb.2018.04.012_bib24) 2002; 118 Meyskens (10.1016/j.abb.2018.04.012_bib19) 2008; 1 Re (10.1016/j.abb.2018.04.012_bib1) 2005; 105 Skoetz (10.1016/j.abb.2018.04.012_bib28) 2017; 5 Zhu (10.1016/j.abb.2018.04.012_bib11) 2012; 29 Viviani (10.1016/j.abb.2018.04.012_bib18) 2011; 365 Gupta (10.1016/j.abb.2018.04.012_bib20) 2013; 15 Mehnert (10.1016/j.abb.2018.04.012_bib6) 2001; 47 Arora (10.1016/j.abb.2018.04.012_bib13) 2015; 19 Chou (10.1016/j.abb.2018.04.012_bib31) 2006; 58 |
| References_xml | – volume: 7 year: 2016 ident: bib25 article-title: Reed-Sternberg cells in Hodgkin's lymphoma present features of cellular senescence publication-title: Cell Death Dis. contributor: fullname: Livneh – volume: 365 start-page: 203 year: 2011 end-page: 212 ident: bib18 article-title: Italiano di Terapie Innovative nei, L. Intergruppo Italiano, ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned publication-title: N. Engl. J. Med. contributor: fullname: Gruppo – volume: 25 start-page: 289 year: 2008 end-page: 297 ident: bib9 article-title: Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting publication-title: J. Microencapsul. contributor: fullname: Katoch – volume: 105 start-page: 4553 year: 2005 end-page: 4560 ident: bib1 article-title: From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential publication-title: Blood contributor: fullname: Diehl – volume: 29 start-page: 3090 year: 2012 end-page: 3101 ident: bib11 article-title: Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles publication-title: Pharmaceut. Res. contributor: fullname: Rigas – volume: 39 start-page: 283 year: 2012 end-page: 299 ident: bib21 article-title: Discovery of curcumin, a component of golden spice, and its miraculous biological activities publication-title: Clin. Exp. Pharmacol. Physiol. contributor: fullname: Aggarwal – volume: 47 start-page: 165 year: 2001 end-page: 196 ident: bib6 article-title: Solid lipid nanoparticles: production, characterization and applications publication-title: Adv. Drug Deliv. Rev. contributor: fullname: Mader – volume: 58 start-page: 621 year: 2006 end-page: 681 ident: bib31 article-title: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies publication-title: Pharmacol. Rev. contributor: fullname: Chou – volume: 5 year: 2017 ident: bib28 article-title: Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma publication-title: Cochrane Database Syst. Rev. contributor: fullname: von Tresckow – volume: 10 start-page: 327 year: 2002 end-page: 335 ident: bib8 article-title: Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues publication-title: J. Drug Target. contributor: fullname: Gasco – volume: 9 start-page: E24 year: 2017 ident: bib14 article-title: Multiple functions of d-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS) as curcumin nanoparticle stabilizer: in vivo kinetic profile and anti-ulcerative colitis analysis in animal model publication-title: Pharmaceutics contributor: fullname: Adnyana – volume: 1 start-page: 32 year: 2008 end-page: 38 ident: bib19 article-title: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial publication-title: Canc. Prev. Res. contributor: fullname: Gerner – volume: 33 start-page: 4802 year: 2013 end-page: 4808 ident: bib12 article-title: The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo publication-title: Mater Sci Eng C Mater Biol Appl contributor: fullname: Xu – volume: 15 start-page: 195 year: 2013 end-page: 218 ident: bib20 article-title: Therapeutic roles of curcumin: lessons learned from clinical trials publication-title: AAPS J. contributor: fullname: Aggarwal – volume: 36 start-page: 454 year: 2018 end-page: 462 ident: bib26 article-title: Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology contributor: fullname: Rambaldi – volume: 2 start-page: 751 year: 2007 end-page: 760 ident: bib5 article-title: Nanocarriers as an emerging platform for cancer therapy publication-title: Nat. Nanotechnol. contributor: fullname: Langer – volume: 19 start-page: 940 year: 2015 end-page: 952 ident: bib13 article-title: Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats publication-title: Eur. J. Pain contributor: fullname: Chopra – volume: 8 start-page: E254 year: 2006 end-page: E262 ident: bib10 article-title: Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice publication-title: AAPS J. contributor: fullname: Murthy – volume: 8 start-page: E24 year: 2016 ident: bib15 article-title: TPGS-stabilized curcumin nanoparticles exhibit superior effect on carrageenan-induced inflammation in wistar rat publication-title: Pharmaceutics contributor: fullname: Adnyana – volume: 6 year: 2014 ident: bib23 article-title: IL-6 in inflammation, immunity, and disease publication-title: Cold Spring Harbor perspectives in biology contributor: fullname: Kishimoto – volume: 28 start-page: 849 year: 2017 end-page: 854 ident: bib29 article-title: ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma publication-title: Ann. Oncol. : official journal of the European Society for Medical Oncology / ESMO contributor: fullname: Deyell – volume: 52 start-page: 1010 year: 2008 end-page: 1030 ident: bib3 article-title: Multi-targeted therapy by curcumin: how spicy is it? publication-title: Mol. Nutr. Food Res. contributor: fullname: Aggarwal – volume: 123 start-page: 56 year: 2008 end-page: 65 ident: bib4 article-title: Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells publication-title: Int. J. Canc. contributor: fullname: Oteiza – volume: 18 start-page: 675 year: 2012 end-page: 680 ident: bib17 article-title: ABVD as the treatment option in advanced Hodgkin's lymphoma patients older than 45 years publication-title: Pathol. Oncol. Res. contributor: fullname: Jakovic – volume: 104 start-page: 413 year: 2016 end-page: 419 ident: bib30 article-title: Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis publication-title: Int. J. Hematol. contributor: fullname: Chen – volume: 25 start-page: 445 year: 2005 end-page: 453 ident: bib16 article-title: Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo publication-title: Eur. J. Pharmaceut. Sci. contributor: fullname: Panchagnula – start-page: 1 year: 2017 end-page: 7 ident: bib27 article-title: Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD x two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy publication-title: Leuk. Lymphoma contributor: fullname: Ng – volume: 42 start-page: 337 year: 2000 end-page: 343 ident: bib7 article-title: Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats publication-title: Pharmacol. Res. : the official journal of the Italian Pharmacological Society contributor: fullname: Gasco – volume: 19 start-page: 346 year: 2012 end-page: 353 ident: bib22 article-title: Native and beta-cyclodextrin-enclosed curcumin: entrapment within liposomes and their in vitro cytotoxicity in lung and colon cancer publication-title: Drug delivery contributor: fullname: Parekh – volume: 75 start-page: 787 year: 2008 end-page: 809 ident: bib2 article-title: Curcumin as “Curecumin”: from kitchen to clinic publication-title: Biochem. Pharmacol. contributor: fullname: Aggarwal – volume: 118 start-page: 195 year: 2002 end-page: 201 ident: bib24 article-title: Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease publication-title: Br. J. Haematol. contributor: fullname: Murray – volume: 19 start-page: 940 issue: 7 year: 2015 ident: 10.1016/j.abb.2018.04.012_bib13 article-title: Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats publication-title: Eur. J. Pain doi: 10.1002/ejp.620 contributor: fullname: Arora – volume: 25 start-page: 445 issue: 4–5 year: 2005 ident: 10.1016/j.abb.2018.04.012_bib16 article-title: Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo publication-title: Eur. J. Pharmaceut. Sci. doi: 10.1016/j.ejps.2005.04.003 contributor: fullname: Varma – volume: 18 start-page: 675 issue: 3 year: 2012 ident: 10.1016/j.abb.2018.04.012_bib17 article-title: ABVD as the treatment option in advanced Hodgkin's lymphoma patients older than 45 years publication-title: Pathol. Oncol. Res. doi: 10.1007/s12253-011-9494-4 contributor: fullname: Andjelic – volume: 39 start-page: 283 issue: 3 year: 2012 ident: 10.1016/j.abb.2018.04.012_bib21 article-title: Discovery of curcumin, a component of golden spice, and its miraculous biological activities publication-title: Clin. Exp. Pharmacol. Physiol. doi: 10.1111/j.1440-1681.2011.05648.x contributor: fullname: Gupta – start-page: 1 year: 2017 ident: 10.1016/j.abb.2018.04.012_bib27 article-title: Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD x two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy publication-title: Leuk. Lymphoma doi: 10.1080/10428194.2017.1376745 contributor: fullname: Kamran – volume: 105 start-page: 4553 issue: 12 year: 2005 ident: 10.1016/j.abb.2018.04.012_bib1 article-title: From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential publication-title: Blood doi: 10.1182/blood-2004-12-4750 contributor: fullname: Re – volume: 2 start-page: 751 issue: 12 year: 2007 ident: 10.1016/j.abb.2018.04.012_bib5 article-title: Nanocarriers as an emerging platform for cancer therapy publication-title: Nat. Nanotechnol. doi: 10.1038/nnano.2007.387 contributor: fullname: Peer – volume: 52 start-page: 1010 issue: 9 year: 2008 ident: 10.1016/j.abb.2018.04.012_bib3 article-title: Multi-targeted therapy by curcumin: how spicy is it? publication-title: Mol. Nutr. Food Res. doi: 10.1002/mnfr.200700354 contributor: fullname: Goel – volume: 42 start-page: 337 issue: 4 year: 2000 ident: 10.1016/j.abb.2018.04.012_bib7 article-title: Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats publication-title: Pharmacol. Res. : the official journal of the Italian Pharmacological Society doi: 10.1006/phrs.2000.0695 contributor: fullname: Fundaro – volume: 123 start-page: 56 issue: 1 year: 2008 ident: 10.1016/j.abb.2018.04.012_bib4 article-title: Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells publication-title: Int. J. Canc. doi: 10.1002/ijc.23477 contributor: fullname: Mackenzie – volume: 25 start-page: 289 issue: 5 year: 2008 ident: 10.1016/j.abb.2018.04.012_bib9 article-title: Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting publication-title: J. Microencapsul. doi: 10.1080/02652040701799598 contributor: fullname: Jain – volume: 58 start-page: 621 issue: 3 year: 2006 ident: 10.1016/j.abb.2018.04.012_bib31 article-title: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies publication-title: Pharmacol. Rev. doi: 10.1124/pr.58.3.10 contributor: fullname: Chou – volume: 104 start-page: 413 issue: 4 year: 2016 ident: 10.1016/j.abb.2018.04.012_bib30 article-title: Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis publication-title: Int. J. Hematol. doi: 10.1007/s12185-016-2080-5 contributor: fullname: Jiang – volume: 33 start-page: 4802 issue: 8 year: 2013 ident: 10.1016/j.abb.2018.04.012_bib12 article-title: The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo publication-title: Mater Sci Eng C Mater Biol Appl doi: 10.1016/j.msec.2013.07.047 contributor: fullname: Wang – volume: 15 start-page: 195 issue: 1 year: 2013 ident: 10.1016/j.abb.2018.04.012_bib20 article-title: Therapeutic roles of curcumin: lessons learned from clinical trials publication-title: AAPS J. doi: 10.1208/s12248-012-9432-8 contributor: fullname: Gupta – volume: 36 start-page: 454 issue: 5 year: 2018 ident: 10.1016/j.abb.2018.04.012_bib26 article-title: Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2017.75.2543 contributor: fullname: Gallamini – volume: 365 start-page: 203 issue: 3 year: 2011 ident: 10.1016/j.abb.2018.04.012_bib18 article-title: Italiano di Terapie Innovative nei, L. Intergruppo Italiano, ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1100340 contributor: fullname: Viviani – volume: 28 start-page: 849 issue: 4 year: 2017 ident: 10.1016/j.abb.2018.04.012_bib29 article-title: ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma publication-title: Ann. Oncol. : official journal of the European Society for Medical Oncology / ESMO doi: 10.1093/annonc/mdx005 contributor: fullname: Marr – volume: 10 start-page: 327 issue: 4 year: 2002 ident: 10.1016/j.abb.2018.04.012_bib8 article-title: Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues publication-title: J. Drug Target. doi: 10.1080/10611860290031868 contributor: fullname: Zara – volume: 47 start-page: 165 issue: 2–3 year: 2001 ident: 10.1016/j.abb.2018.04.012_bib6 article-title: Solid lipid nanoparticles: production, characterization and applications publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/S0169-409X(01)00105-3 contributor: fullname: Mehnert – volume: 29 start-page: 3090 issue: 11 year: 2012 ident: 10.1016/j.abb.2018.04.012_bib11 article-title: Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles publication-title: Pharmaceut. Res. doi: 10.1007/s11095-012-0801-x contributor: fullname: Zhu – volume: 8 start-page: E254 issue: 2 year: 2006 ident: 10.1016/j.abb.2018.04.012_bib10 article-title: Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice publication-title: AAPS J. doi: 10.1007/BF02854895 contributor: fullname: Reddy – volume: 75 start-page: 787 issue: 4 year: 2008 ident: 10.1016/j.abb.2018.04.012_bib2 article-title: Curcumin as “Curecumin”: from kitchen to clinic publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2007.08.016 contributor: fullname: Goel – volume: 118 start-page: 195 issue: 1 year: 2002 ident: 10.1016/j.abb.2018.04.012_bib24 article-title: Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease publication-title: Br. J. Haematol. doi: 10.1046/j.1365-2141.2002.03575.x contributor: fullname: Reynolds – volume: 1 start-page: 32 issue: 1 year: 2008 ident: 10.1016/j.abb.2018.04.012_bib19 article-title: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial publication-title: Canc. Prev. Res. doi: 10.1158/1940-6207.CAPR-08-0042 contributor: fullname: Meyskens – volume: 9 start-page: E24 issue: 3 year: 2017 ident: 10.1016/j.abb.2018.04.012_bib14 article-title: Multiple functions of d-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS) as curcumin nanoparticle stabilizer: in vivo kinetic profile and anti-ulcerative colitis analysis in animal model publication-title: Pharmaceutics doi: 10.3390/pharmaceutics9030024 contributor: fullname: Rachmawati – volume: 7 issue: 11 year: 2016 ident: 10.1016/j.abb.2018.04.012_bib25 article-title: Reed-Sternberg cells in Hodgkin's lymphoma present features of cellular senescence publication-title: Cell Death Dis. doi: 10.1038/cddis.2016.185 contributor: fullname: Gopas – volume: 5 year: 2017 ident: 10.1016/j.abb.2018.04.012_bib28 article-title: Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma publication-title: Cochrane Database Syst. Rev. contributor: fullname: Skoetz – volume: 6 issue: 10 year: 2014 ident: 10.1016/j.abb.2018.04.012_bib23 article-title: IL-6 in inflammation, immunity, and disease publication-title: Cold Spring Harbor perspectives in biology doi: 10.1101/cshperspect.a016295 contributor: fullname: Tanaka – volume: 19 start-page: 346 issue: 7 year: 2012 ident: 10.1016/j.abb.2018.04.012_bib22 article-title: Native and beta-cyclodextrin-enclosed curcumin: entrapment within liposomes and their in vitro cytotoxicity in lung and colon cancer publication-title: Drug delivery doi: 10.3109/10717544.2012.721143 contributor: fullname: Rahman – volume: 8 start-page: E24 issue: 3 year: 2016 ident: 10.1016/j.abb.2018.04.012_bib15 article-title: TPGS-stabilized curcumin nanoparticles exhibit superior effect on carrageenan-induced inflammation in wistar rat publication-title: Pharmaceutics doi: 10.3390/pharmaceutics8030024 contributor: fullname: Rachmawati |
| SSID | ssj0011462 |
| Score | 2.5335782 |
| Snippet | Curcumin reduces Hodgkin's lymphoma (HL) cell growth in vitro, but its unfavorable pharmacokinetics highlight the need for novel in vivo delivery systems.... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 12 |
| SubjectTerms | Curcumin Hodgkin's lymphoma SLN TPGS |
| Title | Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice |
| URI | https://dx.doi.org/10.1016/j.abb.2018.04.012 https://www.ncbi.nlm.nih.gov/pubmed/29679536 https://search.proquest.com/docview/2028947380 |
| Volume | 648 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6TQheEGxcyk1GQiARpcrVSR5LKR088MCGtLfITpwtY0mmppEYv55z7LhpgSFA4iVKrTiJ8n09Pj7-fA4hL4RkoQgZt4vAie3Ak8zm3AltrryF3OeJwFD24VH08SR-Ow_mo5GpOzi0_VekoQ2wxp2zf4H2-qbQAOeAORwBdTj-Ee6zbpl1Van0gxXW5pKYXcmCh5a5dVFewrHmNUyVe0WcdcZbS9ZnWgkgMaMEVoDHFFhNfqqKdUWtdXEFqDcVx_aql8v9KnmtKLECly4hp9YloEEHT9a--6JrlqddqSW6WSOGkL42O5-68mu3ocjFeuQw_xbo6g5R_I1I-hdZf9OrLAvcTZ031mKyGcxwYxRd6e2cOsJmdtlsiUBx3mYnsU7aPpHaUDsonvZ1eTljyZlO2tnb4l6erUd1bZd_Gi906OJ8woVAmV-s0t6ajltpuI_UNmZ4CbCB6BYnO2TPA-MGtnVv-n5-8mG9dgVjj2fqNGIHs5auVIU_POg6b-i62Y7yeo7vkNv9dIVONVnukpGs98nBtOarprqiL6kSEKuVmX1y4405uzkzHDgguSEkHQhJ4ZciJFWEpFuEpEBIaghJDSGxS0_IVy01dMRWpOM98vnd_Hh2aPelPezMT9jK9nPpF_Ahc6ULjt2Aw3mWBCLzwaUOk0SAI-5w6RSBKzzGeVEwz_WZLKAbK0L_Ptmtm1o-JJShj1zwPIuSDEYjV8iCxR4vONxTxEKMyWvzidNLncElNdLG8xTwSBGP1AlSwGNMAgNC2rug2rVMgTG_6_bcAJbC58U1N17LpmvhIi9OgsiPnTF5oJFcv4WXsAjVE4_-7aGPya3hL_SE7K6WnXxKdtq8e9ZT8jteOL4X |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Curcumin+formulated+in+solid+lipid+nanoparticles+has+enhanced+efficacy+in+Hodgkin%27s+lymphoma+in+mice&rft.jtitle=Archives+of+biochemistry+and+biophysics&rft.au=Guorgui%2C+Jacob&rft.au=Wang%2C+Ruixue&rft.au=Mattheolabakis%2C+George&rft.au=Mackenzie%2C+Gerardo+G.&rft.date=2018-06-15&rft.pub=Elsevier+Inc&rft.issn=0003-9861&rft.eissn=1096-0384&rft.volume=648&rft.spage=12&rft.epage=19&rft_id=info:doi/10.1016%2Fj.abb.2018.04.012&rft.externalDocID=S0003986118301929 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-9861&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-9861&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-9861&client=summon |